Table 1. Characteristics of the patients from the CheckMate ICI therapy cohort.
| Variable | Total (N=261) | Data sets | ||
|---|---|---|---|---|
| Training (N=157) | Validation (N=104) | P values | ||
| Gender | 0.890 | |||
| Female | 76 (29.1%) | 45 (28.7%) | 31 (29.8%) | |
| Male | 185 (70.9%) | 112 (71.3%) | 73 (70.2%) | |
| Age (years) | 0.409 | |||
| ≤60 | 122 (46.7%) | 75 (47.8%) | 47 (45.2%) | |
| >60 | 133 (51.0%) | 80 (51.0%) | 53 (51.0%) | |
| Unknown | 6 (2.3%) | 2 (1.3%) | 4 (3.8%) | |
| Metastasis | 0.587 | |||
| No | 191 (73.2%) | 112 (71.3%) | 79 (76.0%) | |
| Yes | 68 (26.1%) | 44 (28.0%) | 24 (23.1%) | |
| Unknown | 2 (0.8%) | 1 (0.6%) | 1 (1.0%) | |
| Sarcoma-like | 0.230 | |||
| No | 195 (74.7%) | 118 (75.2%) | 77 (74.0%) | |
| Yes | 26 (10.0%) | 12 (7.6%) | 14 (13.5%) | |
| Unknown | 40 (15.3%) | 27 (17.2%) | 13 (12.5%) | |
| Rhabdomyoma-like | 0.558 | |||
| No | 205 (78.5%) | 120 (76.4%) | 85 (81.7%) | |
| Yes | 16 (6.1%) | 10 (6.4%) | 6 (5.8%) | |
| Unknown | 40 (15.3%) | 27 (17.2%) | 13 (12.5%) | |
| OS status | 0.785 | |||
| Living | 80 (30.7%) | 47 (29.9%) | 33 (31.7%) | |
| Dead | 181 (69.3%) | 110 (70.1%) | 71 (68.3%) | |
OS, overall survival; ICI, immune checkpoint inhibitor.